Our achievements. Our accomplishments. Our impact.



  • Stem Cell Genomics

    SCN’s Gene Expression Project was made possible through the Network’s collaborative approach to research, and the Project’s use of a single centre to undertake a standardized analysis of hundreds of stem cell lines allowed for the creation of pertinent data and meta-data to be accessed by thousands of researchers around the world.

    READ STORY

  • Stem Cell Plasticity

    Adult stem cells offer great potential as tools or targets of new treatments, and the Stem Cell Network launched a multidisciplinary project early in its mandate in order to discover more about the nature of these mysterious cells.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Patient Engagement

    The Stem Cell Network engaged world-leading researchers and ethicists to provide Canadians with credible and accessible information on the latest advancements in stem cell research.

    READ STORY

  • Cancer Stem Cells

    A seminal Canadian discovery demonstrated that cancer stem cells are a significant reason for high relapse rates after cancer treatments. In recognition of this, the Stem Cell Network has invested heavily finding ways to target and attack them.

    READ STORY

  • Evidence-Based Policy Making

    When the Stem Cell Network launched in 2001, its most pressing goal was to address the policy vacuum that was constraining stem cell research in Canada. SCN and its members provided credible, research-based evidence and recommendations that were critical in the development of Canada’s regulatory landscape for stem cell research.

    READ STORY